Response of authors to Ganju and Dias’ comments on ‘Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful’ by D. A. Parasrampuria and L. Z. Benet

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 6, 2015-12 ,pp. : 367-367

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 1, 2015-07 ,pp. : 44-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase 1, Randomized Ascending Single‐Dose Study of Antagonist Anti‐Human CD40 ASKP1240 in Healthy Subjects

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 13, Iss. 4, 2013-04 ,pp. : 1040-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 10, Iss. 7, 2012-07 ,pp. : 1303-1311

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 162, Iss. 2, 2013-07 ,pp. : 191-201

John Wiley & Sons Inc

Access to resources Recommend Favorite